US Patent

US11202770 — Liquid tasimelteon formulations and methods of use thereof

Formulation · Assigned to Vanda Pharmaceuticals Inc · Expires 2040-12-11 · 15y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects liquid formulations of tasimelteon and methods for their use.

USPTO Abstract

Liquid suspensions of tasimelteon and methods for their use.

Drugs covered by this patent

Patent Metadata

Patent number: US11202770
Jurisdiction: US
Classification: Formulation
Expires: 2040-12-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.